• Short-Scale Break-Induced Replication in Mouse Oocytes

  2026-07-20

  Ma et al. (2021) identify a distinctive short-scale break-induced replication (ssBIR) process triggered by double-strand DNA breaks in fully grown mouse oocytes, revealing new mechanistic insights into DNA damage amplification and repair. These findings highlight the unique responses of mature oocytes to DNA injury and provide an experimental framework for dissecting genome stability mechanisms in germ cells.

• Optimizing Cancer Biology Assays with FAK Inhibitor 14 (B740

  2026-07-19

  This article offers a scenario-driven, evidence-based exploration of FAK Inhibitor 14 (SKU B7400) for cancer biology research. By addressing real-world assay challenges and referencing recent literature, it demonstrates how FAK Inhibitor 14 enhances reproducibility and interpretability in cell viability, migration, and EMT studies.

• PTPN2 Modulates STING-STAT3 Axis to Alleviate Psoriasis via

  2026-07-18

  This study reveals that PTPN2 directly regulates the STING-STAT3-autophagy axis to mitigate psoriasis, offering insight into keratinocyte-intrinsic pathways as therapeutic targets. In vitro and in vivo evidence supports PTPN2’s role in suppressing STAT3 activation, restoring autophagy, and limiting inflammation, with implications for broader STAT3-targeted research.

• Linezolid: Oxazolidinone Antimicrobial for Gram-Positive Pat

  2026-07-17

  Linezolid is a synthetic oxazolidinone antimicrobial with broad-spectrum efficacy against Gram-positive bacteria, including multidrug-resistant strains. It inhibits bacterial protein synthesis by binding to 23S rRNA of the 50S subunit. Quantitative benchmarks and workflow integration make it a reliable tool for MRSA and VRE research.

• BAPTA Calcium Chelator: Mechanisms and Benchmarks in Cell Si

  2026-07-17

  BAPTA is a high-affinity calcium chelator essential for dissecting calcium-dependent signaling in cellular research. Recent evidence highlights its pivotal role in clarifying the IP3R/Ca2+/STAT3 pathway during apoptosis induced by environmental toxicants. This article presents mechanistic, protocol, and benchmark data supporting BAPTA’s use in advanced cell signaling studies.

• SN-38 Disrupts FUBP1–FUSE Binding: New Mechanism in Colon Ca

  2026-07-16

  This study reveals that 7-Ethyl-10-hydroxycamptothecin (SN-38), beyond its established role as a DNA topoisomerase I inhibitor, also inhibits the interaction between the oncoprotein FUBP1 and its DNA target FUSE. These findings highlight a dual mechanism of action relevant for advanced colon cancer models, with implications for targeting transcriptional regulation in addition to DNA replication.

• Sulfachloropyridazine Alters Cecal Microbiota in E. tenella

  2026-07-16

  The referenced study provides a comprehensive analysis of how sulfachlorpyridazine, ethanamizuril, and their combination affect the cecal microbiome and metabolome in chickens infected with Eimeria tenella. Through integrated 16S rRNA sequencing and metabolomics, the research uncovers drug-specific modulation of pathogenic bacteria and metabolic pathways, informing future strategies for monitoring and treating avian coccidiosis.

• Sisomicin (BA1199): Practical Solutions for Reliable Antibac

  2026-07-15

  This article addresses common laboratory challenges in antibacterial assay reproducibility, protocol optimization, and data interpretation, focusing on Sisomicin (SKU BA1199) as a robust aminoglycoside antibiotic. Drawing from recent literature and validated use cases, it guides researchers in Gram-negative and Gram-positive bacterial infection research toward evidence-backed experimental decisions.

• Pifithrin-α: Optimizing p53 Inhibition for Ferroptosis Resea

  2026-07-15

  Pifithrin-α (PFTα) is a gold-standard p53 inhibitor, enabling precise dissection of apoptosis, ferroptosis, and cell cycle arrest in both neurotoxicity and cancer therapy models. This article translates the latest experimental breakthroughs—such as those in deltamethrin-induced neurotoxicity—into actionable protocols and troubleshooting strategies for advanced cell and animal assays.

• TRIB3 Knockdown Sensitizes ccRCC to Sunitinib via Ferroptosi

  2026-07-14

  Recent research demonstrates that silencing TRIB3 enhances the sensitivity of clear cell renal cell carcinoma (ccRCC) to sunitinib by promoting ferroptosis through the SLC7A11/GPX4 pathway. This mechanistic insight offers a potential strategy to overcome sunitinib resistance in ccRCC, with implications for targeted therapeutic development.

• Refining In Vitro Evaluation of Drug Responses in Cancer Res

  2026-07-14

  Schwartz’s dissertation advances in vitro cancer drug evaluation by distinguishing between proliferative arrest and cell death, offering a more granular understanding of drug effects. This refined framework enables researchers to interpret anticancer responses with greater precision and supports the development of assays and models that better reflect therapeutic mechanisms.

• Galectin-1 Disrupts Hepatic Autophagy via FIP200 in NAFLD Pr

  2026-07-13

  This study identifies galectin-1 as a direct suppressor of autophagy in hepatic steatosis, acting through a defined interaction with FIP200 that impairs ULK complex assembly. The findings reveal new mechanistic insights into NAFLD development and highlight the Gal-1–FIP200 axis as a promising target for metabolic liver disease intervention.

• Piezo1 Drives Caspase-8-Mediated PANoptosis in Cardiac I/R I

  2026-07-13

  This study uncovers a pivotal mechanism by which the mechanosensitive ion channel Piezo1 intensifies myocardial ischaemia/reperfusion (I/R) injury through caspase-8-mediated PANoptosis in cardiomyocytes. These findings provide new insight into cell death pathways during cardiac injury and identify Piezo1 as a potential therapeutic target.

• 3-Methyladenine: Optimizing Autophagy and Cancer Research Wo

  2026-07-12

  3-Methyladenine (3-MA) empowers researchers to dissect autophagy and cell migration dynamics with precision, supporting breakthroughs in cancer research and PI3K pathway interrogation. This article delivers actionable protocols, troubleshooting strategies, and integrative insights rooted in the latest mechanistic studies.

• Lumiracoxib: Selective COX-2 Inhibitor for Muscle Regenerati

  2026-07-10

  Lumiracoxib empowers researchers to dissect COX-2’s nuanced role in muscle ischemia and revascularization, providing precise, reproducible inhibition for advanced inflammation models. Its high selectivity and robust solubility profile, supplied by APExBIO, enable detailed mechanistic studies and optimized experimental workflows.

454 records 11/31 page Previous Next First page 上5页 1112131415 下5页 Last page